A Phase 2 interventional study of Duvelisib and Duvelisib in Peripheral T-cell Lymphoma, sponsored by SecuraBio. Completed at 36 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by SecuraBio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States — 21 open to participants now, 28 under way, 2 of them phase 3. Lymphoma, T-Cell, Peripheral · United States.
Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, this one is the 12th largest by enrollment of the 157 interventional ones that give a count, is one of 5 that started in 2018, is one of 54 in phase 2, and was the 109th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →21 of the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States are open now. Recruiting first, the newest first:
Kyowa Kirin, Inc. · Sites in United States, Italy, Spain
Ages 18+
Natera, Inc. · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 78 · Phase 3 5
First in 1988; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 36 across the 157 interventional studies, 800 across the 7 observational. Of the 126 that completed or were terminated, 72 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 164 have an industry lead sponsor. The 10 most frequent:
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
SecuraBio has 2 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
9 of the studies in Lymphoma, T-Cell, Peripheral with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561048Phase 3Corvus Pharmaceuticals, Inc.Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | 2027-11 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT03964480Associazione Angela Serra per la ricerca sul cancroProspective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. | 2026-12-30 |
| NCT07388563National Cancer Institute (NCI)Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | 2027-03-31 |
| NCT04068597CellCentric Ltd.Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 164 studies in Lymphoma, T-Cell, Peripheral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
The study had 2 phases, a Dose Optimization Phase and an Expansion Phase.
In the Dose Optimization Phase, participants were randomly assigned to 1 of 2 study cohorts, as follows:
A total of 20 participants were to be enrolled in the Dose Optimization Phase, with 10 participants per cohort. Based on the safety and activity data obtained in the Dose Optimization Phase of the study, the Expansion Phase dose of duvelisib was to be determined.
In the Expansion Phase, approximately 100-130 participants were to be enrolled and receive duvelisib dose in 28-day cycles as determined in Dose Optimization Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of one of the following histologic subtypes of PTCL, confirmed, as defined by the World Health Organization:
Received at least 2 cycles of one standard regimen for newly diagnosed advanced PTCL, and one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-participant basis to 50 mg and then 75 mg, based on the participant's response to and tolerance of therapy, in 28-day cycles.
Drug: Duvelisib
Duvelisib 75 mg PO BID, administered in 28-day cycles.
Drug: Duvelisib
Duvelisib PO BID at a starting dose of 75 mg for the first 2 cycles, followed by a mandatory reduction to 25 mg BID thereafter for those participants with complete response (CR), partial response (PR) or stable disease (SD), in 28-day cycles (dose determined in Optimization Phase).
Drug: Duvelisib
Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria
ORR was defined as the percentage of participants with CR + PR, as assessed by the investigator using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.
Time frame: 56 days (2 cycles; 28-day cycles)
ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano Criteria
ORR was defined as the percentage of participants with CR + PR, as assessed by the IRC using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.
Time frame: 56 days (2 cycles; 28-day cycles)
Duration of Response (DOR) as Assessed by the Investigator Using the Lugano Criteria
DOR was defined for participants with CR or PR as the time from the date of the first documentation of response (CR or PR) to the date of the first documentation of progressive disease (PD) or death due to any cause. Participants who withdraw from the study for any reason prior to PD and participants who had ongoing response at the time of the data cut were censored at the date of their last response assessment.
Time frame: Up to 70 months
Progression-free Survival (PFS) as Assessed by the Investigator Using the Lugano Criteria
PFS was defined as the time from the date of first treatment to the date of the first radiographic disease progression or death due to any cause, whichever occurred first.
Time frame: Up to 70 months
Disease Control Rate (DCR) As Assessed by the Investigator Using the Lugano Criteria
DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of stable disease (SD) sustained for at least 8 weeks.
Time frame: Up to 8 weeks
DOR as Assessed by the IRC Using the Lugano Criteria
DOR was defined for participants with CR or PR as the time from the date of the first documentation of response (CR or PR) to the date of the first documentation of PD or death due to any cause. Participants who withdrew from the study for any reason prior to PD and participants who had ongoing response at the time of the data cut were censored at the date of their last response assessment.
Time frame: Up to 70 months
PFS as Assessed by the IRC Using the Lugano Criteria
PFS was defined as the time from the date of first treatment to the date of the first radiographic disease progression or death due to any cause, whichever occurred first.
Time frame: Up to 70 months
DCR as Assessed by the IRC Using the Lugano Criteria
DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of SD sustained for at least 8 weeks.
Time frame: Up to 8 weeks
Overall Survival (OS)
OS was defined as the time from the date of first treatment to the date of death due to any cause. Participants without documented death were censored at last alive date.
Time frame: Up to 70 months
Plasma Concentration of IPI-145 (Duvelisib) and IPI-656 (Metabolite)
Blood samples were taken for the analyses of duvelisib and IPI-656 in plasma at designated time points. Results are reported as nanograms/milliliter (ng/mL).
Time frame: Day 15 of Cycles 1 and 2 (4 hours postdose) (28-day cycles)
Regardless of study phase, all participants underwent screening assessments up to 30 days before the first study drug dose.
| Milestone | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| Started | 20 | 13 | 0 |
| Received at least 1 dose of study drug | 20 | 13 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 20 | 13 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 |
| Withdrew: Closure of the study by the sponsor | 3 | 1 | 0 |
| Withdrew: Death | 16 | 11 | 0 |
| Milestone | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| Started | 0 | 0 | 123 |
| Received at least 1 dose of study drug | 0 | 0 | 123 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 123 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Closure of the study by the sponsor | 0 | 0 | 39 |
| Withdrew: Death | 0 | 0 | 78 |
| Withdrew: Progressive disease | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
ORR was defined as the percentage of participants with CR + PR, as assessed by the investigator using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.
| percentage of participants | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 |
|---|---|---|
| Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria | 53.8 (26.7 to 80.9) | 53.8 (26.7 to 80.9) |
ORR was defined as the percentage of participants with CR + PR, as assessed by the IRC using the Lugano criteria, for participants receiving the optimal dose of duvelisib for at least one cycle of study therapy.
| percentage of participants | Expansion Phase |
|---|---|
| ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano Criteria | 48.0 (39.1 to 56.8) |
DOR was defined for participants with CR or PR as the time from the date of the first documentation of response (CR or PR) to the date of the first documentation of progressive disease (PD) or death due to any cause. Participants who withdraw from the study for any reason prior to PD and participants who had ongoing response at the time of the data cut were censored at the date of their last response assessment.
| month | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 |
|---|---|---|
| Duration of Response (DOR) as Assessed by the Investigator Using the Lugano Criteria | 4.22 (1.87 to NA) | 3.32 (1.77 to NA) |
PFS was defined as the time from the date of first treatment to the date of the first radiographic disease progression or death due to any cause, whichever occurred first.
| month | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 |
|---|---|---|
| Progression-free Survival (PFS) as Assessed by the Investigator Using the Lugano Criteria | 3.55 (1.05 to 8.54) | 3.55 (1.81 to 13.14) |
DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of stable disease (SD) sustained for at least 8 weeks.
| percentage of participants | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 |
|---|---|---|
| Disease Control Rate (DCR) As Assessed by the Investigator Using the Lugano Criteria | 61.5 (35.1 to 88.0) | 61.5 (35.1 to 88.0) |
DOR was defined for participants with CR or PR as the time from the date of the first documentation of response (CR or PR) to the date of the first documentation of PD or death due to any cause. Participants who withdrew from the study for any reason prior to PD and participants who had ongoing response at the time of the data cut were censored at the date of their last response assessment.
| month | Expansion Phase |
|---|---|
| DOR as Assessed by the IRC Using the Lugano Criteria | 7.9 (6.4 to 21.00) |
PFS was defined as the time from the date of first treatment to the date of the first radiographic disease progression or death due to any cause, whichever occurred first.
| months | Expansion Phase |
|---|---|
| PFS as Assessed by the IRC Using the Lugano Criteria | 3.4 (1.8 to 3.9) |
DCR was defined as the percentage of participants with a best overall response of CR or PR or with a best overall response of SD sustained for at least 8 weeks.
| percentage of participants | Expansion Phase |
|---|---|
| DCR as Assessed by the IRC Using the Lugano Criteria | 49.6 (40.8 to 58.4) |
OS was defined as the time from the date of first treatment to the date of death due to any cause. Participants without documented death were censored at last alive date.
| month | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| Overall Survival (OS) | 6.70 (5.22 to NA) | 10.58 (6.67 to 44.62) | 12.4 (8.4 to 22.7) |
Blood samples were taken for the analyses of duvelisib and IPI-656 in plasma at designated time points. Results are reported as nanograms/milliliter (ng/mL).
| ng/mL | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| Duvelisib: Cycle 1, Day 15 | 1238.1 ± 787.53 | 2070.0 ± 889.39 | 2873.7 ± 1709.15 |
| Duvelisib: Cycle 2, Day 15 | 1492.5 ± 1019.10 | — | 2648.2 ± 1336.94 |
| Metabolite (IPI-156): Cycle 1, Day 15 | 1310.4 ± 1408.99 | 1580.9 ± 772.13 | 2387.5 ± 1919.33 |
| Metabolite (IPI-156): Cycle 2, Day 15 | 894.8 ± 441.55 | — | 2427.0 ± 1655.89 |
Collected over From start of treatment (Day 1) to end of study (70 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Optimization Phase: Cohort 1 | 16/20 (80%) | 14/20 (70%) | 19/20 (95%) |
| Dose Optimization Phase: Cohort 2 | 11/13 (84.6%) | 9/13 (69.2%) | 13/13 (100%) |
| Expansion Phase | 78/123 (63.4%) | 60/123 (48.8%) | 121/123 (98.4%) |
| Event | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| PyrexiaGeneral disorders | 1/20 | 3/13 | 6/123 |
| PneumoniaInfections and infestations | 4/20 | 0/13 | 4/123 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 2/13 | 9/123 |
| ColitisGastrointestinal disorders | 1/20 | 2/13 | 2/123 |
| Disease progressionGeneral disorders | 3/20 | 0/13 | 10/123 |
| SepsisInfections and infestations | 3/20 | 1/13 | 3/123 |
| Aspartate aminotransferase increasedInvestigations | 2/20 | 0/13 | 3/123 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/20 | 1/13 | 1/123 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/20 | 1/13 | 0/123 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/20 | 1/13 | 2/123 |
| Event | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/20 | 9/13 | 41/123 |
| Platelet count decreasedInvestigations | 11/20 | 6/13 | 34/123 |
| Alanine aminotransferase increasedInvestigations | 4/20 | 7/13 | 47/123 |
| NauseaGastrointestinal disorders | 9/20 | 6/13 | 31/123 |
| FatigueGeneral disorders | 7/20 | 6/13 | 38/123 |
| PyrexiaGeneral disorders | 6/20 | 6/13 | 28/123 |
| Neutrophil count decreasedInvestigations | 8/20 | 3/13 | 41/123 |
| AnaemiaBlood and lymphatic system disorders | 7/20 | 5/13 | 34/123 |
| Aspartate aminotransferase increasedInvestigations | 4/20 | 5/13 | 45/123 |
| White blood cell count decreasedInvestigations | 7/20 | 3/13 | 25/123 |
Safety Analysis Set: all participants who received at least one dose of study drug.
| Age, Continuous(years) | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase | Total |
|---|---|---|---|---|
| Mean | 64.0 ± 14.81 | 65.0 ± 7.22 | 62.9 ± 13.59 | 63.2 ± 13.29 |
| Sex: Female, Male(Participants) | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase | Total |
|---|---|---|---|---|
| Female | 6 | 4 | 56 | 66 |
| Male | 14 | 9 | 67 | 90 |
| Ethnicity (NIH/OMB)(Participants) | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 12 | 14 |
| Not Hispanic or Latino | 18 | 12 | 111 | 141 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 18 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 9 | 11 |
| White | 16 | 12 | 92 | 120 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 4 | 5 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Dose Optimization Phase: Cohort 1 | Dose Optimization Phase: Cohort 2 | Expansion Phase | Total |
|---|---|---|---|---|
| 0 | 8 | 5 | 49 | 62 |
| 1 | 8 | 7 | 64 | 79 |
| 2 | 3 | 1 | 10 | 14 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
| Missing | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Dec 2023, 70 months.
Results were first posted in Feb 2025, 1 year 2 months after primary completion.
Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 70 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib
Lymphoma, T-Cell, Peripheral →